Rankings
▼
Calendar
KLRS Q3 2024 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena
KLRS
Kalaris Therapeutics Inc
$187M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$38M
Net Income
-$38M
EPS (Diluted)
$-7.64
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$4M
Free Cash Flow
-$4M
Stock-Based Comp.
$262,000
Balance Sheet
Total Assets
$2M
Total Liabilities
$92M
Stockholders' Equity
-$89M
Cash & Equivalents
$2M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
-$4M
+100.0%
Operating Income
-$38M
-$47M
+19.4%
Net Income
-$38M
-$44M
+14.0%
← FY 2024
All Quarters
Q4 2024 →